{"entity":{"id":"nct06057831","kind":"trial","name":"PET/MRI in Rectal Cancer","aka":[],"tldr":"A phase 2 trial in colorectal cancer, run by AHS Cancer Control Alberta, not yet recruiting.","summary":"PET/MRI in Rectal Cancer is a phase 2, interventional study registered as NCT06057831 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-05 and due to reach its primary completion in 2029-05. Interventions recorded: Total Neo-adjuvant Therapy; 18FDG-PET/MRI scan. Conditions listed: Rectal Cancer. Primary outcome: The primary endpoint of the study is pathological response (pCR) prediction with PET/MRI.; Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.. Colorectal eligibility wording from the registry: \"Patients with histologically proven adenocarcinoma of the rectum\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06057831","url":"https://clinicaltrials.gov/study/NCT06057831"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06057831","phase":"2","setting":"18FDG-PET/MRI Imaging in Predicting Pathological Response to Total Neo-adjuvant Therapy in Rectal Cancer","sponsor":"AHS Cancer Control Alberta","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06057831/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}